Multiple myeloma: new uses for available agents, excitement for the future.
Anderson KC. J Natl Compr Canc Netw. 2015 May;13(5 Suppl):694-6.
Expanding role of lenalidomide in hematologic malignancies.
Ghosh N et al. Cancer Manag Res. 2015 May 2;7:105-19. doi: 10.2147/CMAR.S81310. eCollection 2015.
A Rare Variant of Multiple Myeloma; Non-Secretory Myeloma with diffuse osteolytic lesions.
Sultan S et al. Gulf J Oncolog. 2015 May;1(18):28-31.
Mapping Functions in Health-Related Quality of Life: Mapping From Two Cancer-Specific Health-Related Quality-of-Life Instruments to EQ-5D-3L.
Young TA et al. Med Decis Making. 2015 May 21. pii: 0272989X15587497. [Epub ahead of print].
Clinical Dilemmas:When to Recommend Allogeneic Transplantation in Multiple Myeloma.
Gertz MA et al. Leuk Lymphoma. 2015 May 20:1-12. [Epub ahead of print].
When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy.
Oostendorp M et al. Transfusion. 2015 May 18. doi: 10.1111/trf.13150. [Epub ahead of print].
Cancer Mortality through 2005 among a Pooled Cohort of U.S. Nuclear Workers Exposed to External Ionizing Radiation.
Schubauer-Berigan MK et al. Radiat Res. 2015 May 26. [Epub ahead of print].
The multiple myeloma bone eco-system and its relation to oncogenesis.
Bataille R et al. Morphologie. 2015 May 21. pii: S1286-0115(15)00024-7. doi: 10.1016/j.morpho.2015.03.002. [Epub ahead of print].
Advances in the pathogenesis and diagnosis of multiple myeloma.
Chesi M et al. Int J Lab Hematol. 2015 May;37 Suppl 1:108-14. doi: 10.1111/ijlh.12360.
MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?
Gambella M et al. Expert Rev Mol Diagn. 2015 May 12:1-13. [Epub ahead of print].
Parental Age at Birth and Risk of Hematological Malignancies in Older Adults.
Teras LR et al. Am J Epidemiol. 2015 May 11. pii: kwu487. [Epub ahead of print].
Preclinical and clinical development of an anti-kappa free light chain mAb for multiple myeloma.
Hutchinson AT et al. Mol Immunol. 2015 May 8. pii: S0161-5890(15)00372-7. doi: 10.1016/j.molimm.2015.04.013. [Epub ahead of print].
“How Long Do I Have?”-Story of a Myeloma Patient.
Dhillon WS. Oncologist. 2015 May 8. pii: theoncologist.2015-0047. [Epub ahead of print].
Molecular pathogenesis of multiple myeloma.
Furukawa Y et al. Int J Clin Oncol. 2015 May 8. [Epub ahead of print].
Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Qiao SK et al. Chin Med J (Engl). 2015 5th May;128(9):1215-1222. doi: 10.4103/0366-6999.156134.
Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.
Kuroda J et al. Expert Rev Anticancer Ther. 2015 May 6:1-18. [Epub ahead of print].
The Risk of Secondary Primary Malignancies (SPM) after Therapy for Multiple Myeloma.
Areethamsirikul N, et al. Leuk Lymphoma. 2015 May 7:1-31. [Epub ahead of print].
Lenalidomide: A Review of Its Continuous Use in Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Stem-Cell Transplantation.
McCormack PL et al. Drugs Aging. 2015 Apr 30. [Epub ahead of print].
New treatments highlighted for lymphoma and multiple myeloma.
Printz C. Cancer. 2015 May 15;121(10):1530-1. doi: 10.1002/cncr.29431.
Clinical analysis of 152 cases of multiple primary malignant tumors in 15,398 patients with malignant tumors.
Liu Z et al. PLoS One. 2015 May 6;10(5):e0125754. doi: 10.1371/journal.pone.0125754. eCollection 2015.
Risk of cancer among firefighters in California, 1988-2007.
Tsai RJ et al. Am J Ind Med. 2015 May 6. doi: 10.1002/ajim.22466. [Epub ahead of print].
Proteasome Inhibitors.
Teicher BA et al. Biochem Pharmacol. 2015 Apr 29. pii: S0006-2952(15)00213-0. doi: 10.1016/j.bcp.2015.04.008. [Epub ahead of print].
Treatment of relapsed multiple myeloma.
Cooper DL. N Engl J Med. 2015 Apr 30;372(18):1774. doi: 10.1056/NEJMc1501348#SA1.
Treatment of relapsed multiple myeloma.
Stewart AK et al. N Engl J Med. 2015 Apr 30;372(18):1774-5. doi: 10.1056/NEJMc1501348.